Detalle Publicación

ARTÍCULO
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Autores: Martínez-López, J.; Paiva, Bruno; Lopez-Anglada, L.; Mateos, M. V.; Cedena, T.; Vidriales, M. B.; Auxiliadora Saez-Gomez, M.; Contreras, T.; Oriol, A.; Rapado, I.; Teruel, A. I. ; Cordón, L.; Jesus Blanchard, M.; Bengoechea, E.; Palomera, L.; de Arriba, F.; Cueto-Felgueroso, C.; Orfao, A.; Bladè, J.; San Miguel Izquierdo, Jesús; Jose Lahuerta, J.; GEM / PETHEMA Cooperative Study Group
Título de la revista: BLOOD
ISSN: 0006-4971
Volumen: 126
Número: 7
Páginas: 858 - 862
Fecha de publicación: 2015
Resumen:
Stringent complete response (sCR) criteria are used in multiple myeloma as a deeper response category compared with CR, but prospective validation is lacking, it is not always clear how evaluation of clonality is performed, and is it not known what the relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clonality to define more sCR. To clarify this controversy, we focused on 94 patients that reached CR, of which 69 (73%) also fulfilled the sCR criteria. Patients with sCR displayed slightly longer time to progression (median, 62 vs 53 months, respectively; P = .31). On analyzing this contribution to the prognosis of sFLCr or clonality, it was found that the sFLCr does not identify patients in CR at distinct risk; by contrast, low-sensitive multiparametric flow cytometry (MFC) immunophenotyping (2 colors), which is equivalent to immunohistochemistry, identifies a small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless, using traditional 4-color MFC, persistent clonal BM disease was detectable in 36% of patients, who, compared with minimal residual disease-negative cases, had a significantly inferior outcome. These results show that the current definition of sCR should be revised.